ORCID Profile
0000-0002-8262-628X
Current Organisation
Patan Academy of Health Sciences (PAHS)
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Nepal Journals Online (JOL)
Date: 28-09-2021
Abstract: Introduction: Coronavirus Disease 2019 (COVID-19) vaccines have an important role in the control and prevention of the pandemic. However, infection after vaccination, though uncommon, has been reported after partial or complete immunization. This study aims to find out vaccine breakthrough infection after the Covishield COVID-19 vaccine. Method: This cross-sectional survey was conducted among the health care workers (HCWs) from May 2021 to July 2021 at Patan Hospital, Patan Academy of Health Sciences, Nepal who received the Covishield vaccine. The data were collected using Google form and a printed questionnaire on COVID 19 breakthrough infection ≥2w after vaccination. The rate of breakthrough infection, hospitalization, and its association with age, gender, and working departments of HCWs was analyzed using SPSS. Ethical approval was obtained. Result: Out of 1462 HCWs approached, 880 completed the survey, among which 819 (93.1%) had a completed vaccination status. Infection after the first and before the second dose was 164 (18.7% of 880) and after two doses 131 (16%). The breakthrough infection occurred in 83 (10.1% of 819). There was no statistically significant association of breakthrough infection with age, gender, and working department of HCWs. Total 74 (8.4%) were managed by admission in hospital. Conclusion: The findings of this study reveal a low breakthrough infection rate after Covishield vaccination among HCWs at Patan Academy of Health Sciences, Kathmandu, Nepal. Overall, COVID-19 infection rates decreased after the first and second dose of the vaccine.
Publisher: Bioscientifica
Date: 26-03-2010
DOI: 10.1677/JOE-10-0029
Abstract: Previously, pretreatment with estradiol benzoate (EB) was found to modulate the response of hypothalamic–pituitary–adrenal (HPA) axis and gene expression in several catecholaminergic neuronal locations in ovariectomized (OVX) rats exposed to single immobilization stress (IMO). Here, we investigated the role of estrogen receptor (ER) subtypes, using selective agonists for ERα (propyl pyrazole triol, PPT) or ERβ (WAY-200070) in two major central noradrenergic systems and the HPA axis after exposure to single and repeated IMO. OVX female rats received 21 daily injections of either EB (25 μg/kg), PPT (10 mg/kg), WAY-200070 (10 mg/kg), or vehicle. Injections of EB and PPT, but not WAY-200070, elicited reduced body weight and increased uterine weight, showing their selectivity. Both EB and PPT increased corticosterone levels about two- to threefold, but prevented any further rise with either single or repeated IMO, indicating an ERα (ESR1)-, but not ERβ (ESR2)-, mediated mechanism. In the locus coeruleus (LC), the rise in dopamine-β-hydroxylase ( Dbh ) mRNA with both stress paradigms was abrogated in EB- or PPT-injected animals. However, WAY-200070 blocked the response of DBH mRNA to single IMO but not to repeated IMO. In the nucleus of the solitary tract (NTS), the rise in tyrosine hydroxylase and DBH mRNAs with both IMOs was absent, or greatly attenuated, in EB- or PPT-treated rats. In most cases, WAY-200070 inhibited the response to single IMO but not to repeated IMO. The results demonstrate that pretreatment with estradiol, or ER-selective agonists, modulates the stress-triggered induction of gene expression of norepinephrine biosynthetic enzymes in LC and NTS, with ER selectivity depending on duration of the stress.
Publisher: Elsevier BV
Date: 02-2010
DOI: 10.1016/J.PHYSBEH.2009.07.011
Abstract: Within the catecholaminergic systems, there are contradictory findings regarding ability of estradiol to regulate expression of genes related to catecholamine biosynthesis. Several parameters important for effects of estradiol on the catecholamine (CA) related enzyme gene expression were examined in two CA regions. Ovariectomized (OVX) female rats were given prolonged estradiol treatments, either in a pulsatile fashion by injections or continuously by pellets. The mode affected the response of tyrosine hydroxylase (TH) and GTP cyclohydrolase I (GTPCH) mRNAs differentially in the nucleus of solitary tract (NTS) and the locus coeruleus (LC). In rostral-medial NTS, TH mRNA levels were increased with injections, but declined in rats administered estradiol by pellets. In LC, a significant change was only observed in GTPCH with injections. These differences may reflect activation of different estrogen receptors (ER). The response to estradiol in the presence of ERalpha and ER beta was examined in PC12 cell culture. Estradiol directly regulated promoter activity of TH, GTPCH and dopamine beta-hydroxylase (DBH) genes. With ERalpha, 17 beta-estradiol elevated TH promoter activity, while there was a decline with ERbeta. In contrast, both DBH and GTPCH promoters were enhanced by 17 beta-estradiol over a wide range of concentrations with either ER subtype. Thus, mode of administration, location examined and ER subtype expressed are important considerations in the overall response of catecholamine related enzymes to estradiol.
Publisher: American Physiological Society
Date: 15-12-2014
DOI: 10.1152/PHYSIOLGENOMICS.00084.2014
Abstract: Hypertension is a serious risk factor for myocardial infarction, heart failure, vascular disease, stroke, and renal failure. Like other complex diseases, hypertension is caused by a combination of genetic and environmental factors. The renin-angiotensin-aldosterone system plays an important role in the regulation of blood pressure. The octapeptide angiotensin II (ANG II) is one of the most active vasopressor agents and is obtained from the precursor molecule, angiotensinogen, by the combined proteolytic action of renin and angiotensin-converting enzyme. ANG II increases the expression of aldosterone synthase (coded by Cyp11B2 gene), which is the rate-limiting enzyme in the biosynthesis of aldosterone. Previous studies have shown that increased expression of aldosterone synthase increases blood pressure and cardiac hypertrophy in transgenic mice. Human Cyp11B2 gene has a T/C polymorphism at −344 positions in its 5′-untranslated region (UTR), and the −344T allele is associated with hypertension. Human Cyp11B2 gene also has an A/G polymorphism at 735 position in its 3′-UTR (rs28491316) that is in linkage disequilibrium with single nucleotide polymorphism at −344. We show here that 1) microRNA (miR)-766 binds to the 735G-allele and not the 735A-allele of the hCyp11B2 gene and 2) transfection of miR-766 reduces the human aldosterone synthase mRNA and protein level in human adrenocortical cells H295R. These studies suggest that miR-766 may downregulate the expression of human aldosterone synthase gene and reduce blood pressure in human subjects containing −344T allele.
Publisher: Nepal Journals Online (JOL)
Date: 27-05-2021
Abstract: After a year of the COVID-19 pandemic, the meta-analysis in Dec 2020 did not support its reinfections. Now it’s clear that not only reinfection following earlier exposure is a reality, but also breakthrough infections after vaccinations have been increasingly reported. A breakthrough infection means that the infection has broken through the protection provided by the vaccine. The course of the disease, strict observation for preventive measures, together with safe vaccines is necessary long-term solutions. The effectiveness of the vaccine, durability of immunity, the role of the virus variants, the incidence and severity of breakthrough infections are the challenges in real life. A breakthrough infection is the detection of SARS-CoV-2 RNA or antigen in the respiratory specimen ≥14 days after inoculation of a vaccine. A breakthrough infection of 0.04 to 13% has been reported in the literature. Nepal began vaccine rollout in late Jan 2021. Nearly 3 million population has been vaccinated by two vaccines, the Covishield (AstraZeneca, from India) and Vero Cell (Sinopharm, China). Only minor ‘Adverse Event Following Immunization’ after the initial vaccine rollout has been reported. There is a lack of reports on the breakthrough infection for these vaccines in the local population. Analysis of the data on breakthrough infection from the vaccine rollouts in Nepal is awaited.
Location: United States of America
No related grants have been discovered for Shreekrishna Maharjan.